ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Nationwide Survey of People with Seborrehic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

25 May 2022 08:00:01 By Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update

05 May 2022 16:01:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 May 2022 08:00:04 By Nasdaq GlobeNewswire

Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis

06 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Arcutis Highlights Growth Opportunities at Investor Day in Advance of 2022 Catalysts

28 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Arcutis Presents New Data on Once-Daily Roflumilast Cream for Plaque Psoriasis from DERMIS Phase 3 Trials at American Academy of Dermatology Annual Meeting

25 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

Arcutis’ Roflumilast Foam Demonstrates Clinically Meaningful Results and Patient Quality of Life Improvements in Phase 2 Seborrheic Dermatitis Study

25 Mar 2022 07:30:00 By Nasdaq GlobeNewswire

National Survey Reveals Insights into Emotional Impact of Psoriasis and Illuminates Need for New Topical Treatments

22 Mar 2022 08:00:02 By Nasdaq GlobeNewswire

Arcutis to Host Investor Day on March 28

21 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Mar 2022 16:05:00 By Nasdaq GlobeNewswire